Aceragen Inc - Company Profile
Powered by 
All the data and insights you need on Aceragen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Aceragen Inc Strategy Report
- Understand Aceragen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aceragen Inc (Acragen), formerly Idera Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company, which focuses on the discovery, strategic clinical development, and commercialization of therapeutic drug candidates for the treatment of cancer and rare diseases. It is developing ACG-801 and ACG-701. It intends to develop treatments for CF PEx and melioidosis through the development of ACG-701 and to treat Faber disease through the development of ACG-801. During FY2022, the company discontinued its development of tilsotolimod (IMO-2125). Aceragen is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
15 TW Alexander Drive, Durham, North Carolina, 27709
Website
www.aceragen.com
Telephone
1 484 3481600
No of Employees
26
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$4.9M
Aceragen Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| ACG-801 |
| ACG-701 |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In January, the company announced name change to Aceragen Inc. |
| 2022 | Acquisitions/Mergers/Takeovers | In September, the company acquired Aceragen, a rare disease biopharmaceutical company. |
| 2021 | Acquisitions/Mergers/Takeovers | In November, the company acquired Arrevus, a clinical-stage biotechnology company. |
Competitor Comparison
| Key Parameters | Aceragen Inc | GSK plc | Dynavax Technologies Corp | Exicure Inc | Chinook Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Durham | Brentford | Emeryville | Chicago | Seattle |
| State/Province | North Carolina | England | California | Illinois | Washington |
| No. of Employees | 26 | 70,212 | 408 | 7 | 214 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vincent J. Milano | Chairman | Executive Board | 2022 | 59 |
| John Taylor | Chief Executive Officer; Director | Executive Board | 2022 | 53 |
| John J. Kirby | Chief Financial Officer; Senior Vice President | Senior Management | 2019 | 51 |
| Daniel Soland | Chief Operating Officer; Senior Vice President | Senior Management | 2021 | 63 |
| Daniel Salain | Chief Operating Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer